Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession. RLS Global ("RLS") has over the past few years, under Karin Fischer's leadership, transformed into a commercial stage wound care company.

The expansion in Europe is well underway through partnership with ConvaTec, which is responsible for the commercialization of ChloraSolv in these markets. European regulatory approval for ChloraSolv, the company's main product for debridement of hard-to-heal wounds, has been secured and the product is launched in certain European countries. As previously communicated, RLS' strategic focus is on expanding ChloraSolv into new indications and therapeutic areas, such as burns, pressure ulcers and animal care, through clinical trials generating further clinical evidence.

The focus is also on expanding into new geographies through the partnership with ConvaTec and/or with other leading companies.